Core Insights - Henry Schein, Inc. (HSIC) has expanded its agreement with vVARDIS, gaining exclusive U.S. distribution rights for the drill-free Curodont Repair Fluoride Plus product, effective January 1, 2026, which is expected to enhance the company's Dental business [1][8] - Following the announcement, HSIC shares increased by 0.1%, closing at $73.15 in after-market trading [2] - The company's revenue growth is supported by niche acquisitions and partnerships, with expectations for the latest news to bolster stock performance [3] Company Developments - Curodont is a proprietary solution for treating early-stage cavities without drills or needles, addressing a significant unmet need in dental care [5][6] - The expanded partnership with vVARDIS will enhance Henry Schein's reach across various dental care areas, including general dentistry, orthodontics, and pediatric dentistry [7][8] - Henry Schein is currently the market leader in selling Curodont to general practitioners and Dental Service Organizations (DSOs) in the U.S. and holds exclusive distribution rights in the U.K. [9] Market Outlook - The global dental caries treatment market is projected to grow from $8.01 billion in 2025 to approximately $12.11 billion by 2034, at a CAGR of 4.70% [10] - The rising prevalence of dental diseases necessitates effective treatment options, which supports the growth of the dental caries treatment market [10] Additional Innovations - Henry Schein's dental software business has introduced AI and automation workflows to enhance operational efficiency for dental practices [11] Stock Performance - Year-to-date, HSIC shares have increased by 5.7%, compared to the industry's growth of 15.6% [12]